New antibiotic compound enters phase I clinical trial

November 9, 2011, Wellcome Trust
New antibiotic compound enters phase I clinical trial
False colour light micrograph of Clostridium difficile. Credit: Derren Ready, Wellcome Images.

(Medical Xpress) -- Novacta Biosystems has commenced dosing of the first healthy volunteers in a phase I clinical trial of a new antibiotic to treat the hospital superbug Clostridium difficile.

Laboratory studies have shown that the new compound, NVB302, is effective against all strains of difficile tested, without adversely affecting the healthy bacteria that are normally found in the gut.

Developed with support from a Wellcome Trust Strategic Translation Award, NVB302 is now being tested in a first-in-man trial to determine the safety and tolerability of the compound in healthy volunteers.

C. difficile is a hospital-acquired infection that causes severe and can be life threatening, particularly for the elderly. Few currently available are effective against C. difficile infection and is a growing threat.

Ted Bianco, Director of Technology Transfer at the Wellcome Trust, said: "C. difficile is a particularly insidious infection that catches people at their most vulnerable. With the ever-present threat of increasing drug resistance, taking this new antibiotic into is a significant step on the road to replenishing our depleted medicine cabinet."

NVB302 is a member of a class of antibiotics known as the type B lantibiotics, a naturally occurring class of antibiotic compounds found in many bacteria. Lantibiotics have shown great potential to treat superbug infections such as C. difficile and MRSA; however, conventional has not been able to optimise the structure of the naturally occurring compounds into a form with the potential to treat human disease.

Novacta's proprietary technologies have allowed the structural manipulation and optimisation of the lantibiotics' , to unlock the potential of this novel and underexploited class of compounds.

"We are very pleased to announce the initiation of clinical studies with NVB302," said Dr Mike Dawson, Chief Scientific Officer of Novacta. "This is a major milestone for the company."

Dr Richard Garraway, a Partner in CPHA and member of the Novacta Board of Directors, added: "Celtic is delighted that Novacta has achieved this significant milestone. We are committed to supporting the company through this clinical programme and to work with Novacta in securing an attractive partner for the late-stage clinical development and commercialisation of NVB302."

Explore further: New antibiotic for hospital superbug looks promising

Related Stories

New antibiotic for hospital superbug looks promising

October 12, 2010
A new class of antibiotic specifically designed to target the hospital superbug Clostridium difficile has proved to be more effective than current treatments in preclinical studies.

Thuricin CD tested as specific antibiotic for Clostridium difficile

May 3, 2010
A University of Alberta researcher is part of an international team that has discovered a naturally occurring micro-organism that directly targets a bacteria that causes a sometimes deadly intestinal disease in young children ...

C. difficile and antibiotics not necessarily linked

October 7, 2008
The latest study by Dr. Sandra Dial from the Research Institute of the MUHC, McGill University, and Attending Staff in the Intensive Care Unit at the Jewish General Hospital, questions the assumption held by a vast majority ...

Hope for powerful new C diff. treatment

September 19, 2011
MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly ...

Hospital superbug debugged

October 13, 2011
An international team of scientists led by Monash University researchers has uncovered how a common hospital bacterium becomes a deadly superbug that kills increasing numbers of hospital patients worldwide and accounts for ...

The balance shifts

May 27, 2008
The risk of contracting a Clostridium difficile infection following operations for which a "prophylactic" antibiotic is given to prevent infection is 21 times greater now than it was just a decade ago, according to researchers ...

Recommended for you

Study: What patients really think about opioid vs non-opioid medications for chronic pain

August 14, 2018
Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone ...

Doctors nudged by overdose letter prescribe fewer opioids

August 9, 2018
In a novel experiment, doctors got a letter from the medical examiner's office telling them of their patient's fatal overdose. The response: They started prescribing fewer opioids.

Benzodiazepine and related drug prescriptions have increased among young people in Sweden

August 7, 2018
The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 ...

Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults

August 7, 2018
Getting wisdom teeth removed may be a rite of passage for many teens and young adults, but the opioid painkiller prescriptions that many of them receive could set them on a path to long-term opioid use, a new study finds.

Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

August 1, 2018
A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly ...

US opioid use not declined, despite focus on abuse and awareness of risk

August 1, 2018
Use of prescription opioids in the United States has not substantially declined over the last decade, despite increased attention to opioid abuse and awareness of their risks, finds a study published by The BMJ today.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.